From Cancer to Neuroprotection: Pazopanib Modulates the RIPK1/RIPK3/MLKL and PGAM5/DRP1 Pathways in 3‐ Nitropropionic Acid‐Induced Huntington's Disease
- 27 January 2026
- journal article
- Published by Wiley in Drug Development Research
- Vol. 87 (2) , e70238
Abstract
Huntington's disease (HD) is a progressive neurodegenerative disorder with a poorly understood neurobiological basis. Among the various forms of programmed cell death implicated in neurodegeneration, necroptosis has recently garnered significant attention. Notably, dysregulated necroptosis provokes immune response that drives excessive pro‐inflammatory cytokine production, promoting further necroptotic cell death through TNF‐α/RIPK1 signaling. Consequently, necroptosis exacerbates neuroinflammation, contributing to the progression of different neurodegenerative diseases. However, the precise role of necroptosis in HD pathogenesis remains unclear. Given the growing interest in repurposing FDA‐approved drugs for novel therapeutic interventions, this study investigates the anti‐cancer agent Pazopanib (Pazo) as a potential neuroprotective approach for HD. This study assesses Pazo's ability to mitigate necroptosis by targeting the RIPK1/RIPK3/MLKL pathway in a model of HD produced by 3‐nitropropionic acid (3‐NP). Sixty male Wistar rats were randomly assigned to four groups: Group I received normal saline; Group II received Pazo (15 mg/kg, i.p.); Group III received 3‐NP (10 mg/kg, i.p.); and Group IV received 3‐NP (10 mg/kg, i.p.) and Pazo (15 mg/kg, i.p.). Behavioral assessments, including open field, rotarod, and wire hanging tests, demonstrated that Pazo significantly improved motor function. At the molecular level, Pazo inhibited PGAM5, a key regulator of mitochondrial fission, effectively reversing the RIPK1/RIPK3/MLKL necroptotic cascade and the consequent immune activation. This suppression of necroptosis was associated with reduced microgliosis, neuroinflammation and enhanced neuronal survival within the striatum. These findings highlight the potential of Pazo as a neuroprotective agent against HD by leveraging its antioxidant, anti‐inflammatory, immune‐modulating, and anti‐necroptotic properties.Keywords
This publication has 56 references indexed in Scilit:
- Bromelain Alleviates 3‐Nitropropionic Acid‐Induced Huntington's Disease‐Like Symptoms in Rats Through the Interplay of SIRT1 / PGC ‐1α and FOXO3a PathwaysBioFactors, 2025
- Azilsartan Attenuates 3-Nitropropinoic Acid-Induced Neurotoxicity in Rats: The Role of IĸB/NF-ĸB and KEAP1/Nrf2 Signaling PathwaysNeurochemical Research, 2024
- Cognitive enhancing effects of pazopanib in D‑galactose/ovariectomized Alzheimer’s rat model: insights into the role of RIPK1/RIPK3/MLKL necroptosis signaling pathwayInflammopharmacology, 2023
- Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta‐AnalysisMovement Disorders, 2022
- Functional suppression of Ripk1 blocks the NF-κB signaling pathway and induces neuron autophagy after traumatic brain injuryMolecular and Cellular Biochemistry, 2020
- Rutin and Selenium Co-administration Reverse 3-Nitropropionic Acid-Induced Neurochemical and Molecular Impairments in a Mouse Model of Huntington’s DiseaseNeurotoxicity Research, 2019
- Effect of rutin against a mitochondrial toxin, 3-nitropropionicacid induced biochemical, behavioral and histological alterations-a pilot study on Huntington’s disease model in ratsMetabolic Brain Disease, 2016
- Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseasesCellular and Molecular Life Sciences, 2012
- CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approachesAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976